Mutant of granulocyte-colony stimulating factor (G-CSF) and chemically conjugated polypeptide thereof

• US 8,841,426 B2
• Filed: 07/19/2006
• Issued: 09/23/2014
• Est. Priority Date: 07/20/2005
• Status: Active Grant

• Current Assignee: Mogam Biotechnology Research Institute
• Original Assignee: Mogam Biotechnology Research Institute
• Inventors: Kang, Kwan-Yub, Hong, Jeong-Woon
• Primary Examiner(s): Shafer, Shulamith H
• Application Number:
  US11/995,968
• Publication Number:
  US 20080200657A1
• Time in Patent Office: 2,988 Days
• Field of Search: None
• US Class Current: 530/399
• CPC Class Codes: A61K 47/60 the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: C07K 14/535 Granulocyte CSF; Granulocyte-macrophage CSF

Abstract

Provided are mutants of human granulocyte-colony stimulating factor (G-CSF) designed for specific chemical conjugation, and chemical conjugates thereof for use as an adjuvant in the treatment of cancer. The present invention provides a mutant of a G-CSF in which a threonine (Thr) residue at position 133 of G-CSF comprising the amino acid sequence identified in SEQ ID NO: 1 is substituted with a cysteine (Cys) residue. In addition, the invention provides a mutant of a G-CSF in which a cysteine (Cys) residue is inserted between a glycine (GIy) residue at position 135 and an alanine (Ala) residue at position 136 of G-CSF. Further, the invention provides a chemically conjugated mutant G-CSF to which biocompatible polymer such as polyethylene glycol (PEG) was attached at the cysteine residue, which was introduced by the substitution or insertion mutation, increasing its in vivo retention time without reducing in vivo biological activity due to the conjugation with the biocompatible polymer, thereby ultimately extending the in vivo biological activity.

Claims

1. A mutant of an isolated human granulocyte-colony stimulating factor (G-CSF), the mutant comprising the amino acid sequence of SEQ ID NO:

5.

2. A conjugated mutant of an isolated human granulocyte-colony stimulating factor (G-CSF) comprising a mutant of a human G-CSF and a nonprotein chemical compound, wherein the mutant comprises the amino acid sequence of SEQ ID NO:

5, and wherein the nonprotein chemical compound is attached to the cysteine residue at position 136 of SEQ ID NO;

5.

3. The conjugated mutant of claim 2, wherein the mutant has a substitution at position 17 of SEQ ID NO:

5, the substitution replacing cysteine with serine.

4. The conjugated mutant of claim 2 or 3, wherein the nonprotein chemical compound is selected from the group consisting of polyethylene glycol (PEG), polyvinyl alcohol (PVA), polycarboxylic acid and polyvinyl pyrrolidone, binding with a compound selected from the group consisting of maleimide, vinyl sulfone, iodacetamide and orthopyridyl disulfide.

5. The conjugated mutant of claim 2 or 3, wherein the nonprotein chemical compound has a molecular weight in the range of about 2 to about 100 kDa.

6. The conjugated mutant of claim 4, wherein the PEG has a molecular weight in the range of about 5 to about 100 kDa.